Collaborative Research Agreement Amendment 5, dated as of January 17, 2020 by and between National Taiwan University and PTC Therapeutics GT, Inc

EX-10.1 2 ptct-20200930ex101c45b08.htm EX-10.1


Collaborative Research Agreement Amendment 5

This Amendment 5 is made and entered into as of the last date signed below (the "Amendment 5 Effective Date") to that certain Collaborative Research Agreement dated September 30, 2015 (as amended, the "Agreement") by and between National Taiwan University at No. 1, Sec. 4, Roosevelt Road, Taipei, 10617 Taiwan (R.O.C) (hereinafter "NTU") and PTC Therapeutics GT, Inc. (formerly Agilis Biotherapeutics), a Delaware corporation duly organized under law and having an address at 6 Kimball Lane, Suite 320, Lynnfield, Massachusetts, 01940 USA (hereinafter "COMPANY"). Capitalized terms herein shall have the meaning ascribed to them in the Agreement. To the extent of any conflict with the prior amendments to the Agreement, this Amendment 5 supersedes the prior amendments.

WHEREAS, the COMPANY and NTU previously amended the agreement via Amendments 1 through 4. In Amendment 4, the COMPANY and NTU agreed to a three year extension of the Term from October 1, 2017 to September 30, 2020; extension and expansion of the AADC-010 and the 011 Phase IIb protocol studies and related research; and corresponding increases in the Budget.

NOW, THEREFORE, the COMPANY and NTU wish to further amend the Agreement as follows:

1.No-Cost Extension of the Term and the AADC-010 and 011 Phase IIb protocol studies:

The parties hereby agree that the Term and the duration of the AADC-010 and the 011 Phase IIb protocol studies are further extended, from September 30, 2020 to December 31, 2020, at no additional cost.

2.Additional Research Project and Objectives of Amendment 5:

The parties hereby agree that the additional research activities shall be conducted under this Amendment 5:


3.Additional Research Budget for Amendment 5:

Per Section 3.1 of the Agreement, it is agreed to and understood by the parties that NTU shall be paid for the Project and Research Cost for Amendment 5, as set forth below:

Cost [**]: [**] NTD

[**] cost: [**] NTD [**]
Overhead (OH): [**] NTD ([**]% through collaborator research agreement) OH=[**]


Per Section 3.2 of the Agreement, the Research Costs shall be invoiced by NTU [**] (invoices to be emailed to [**] and [**]) based on screenings completed, and Company shall pay such invoices within [**] of receipt.  

IN WITNESS WHEREOF, both NTU and COMPANY have executed this Amendment 5, in duplicate originals, by their respective and duly authorized officers on the day and year written.

[Signature Block to Follow]



By: /s/ Matthew Klein

By: /s/ Chung-Ming Kuan

Authorized Signature

Authorized Signature

Matthew Klein, MD, MS, FACS

Global Head Gene and

Mitochondrial Therapies

Printed Name & Title

17-Jan-2020 14:49:05 EST